Available treatment options for the management of Lambert-Eaton myasthenic syndrome.
about
The Production Processes and Biological Effects of Intravenous ImmunoglobulinUpdate on treatment options for Lambert-Eaton myasthenic syndrome: focus on use of amifampridineSynaptic Pathophysiology and Treatment of Lambert-Eaton Myasthenic Syndrome.Genetic variation in aryl N-acetyltransferase results in significant differences in the pharmacokinetic and safety profiles of amifampridine (3,4-diaminopyridine) phosphate.Electrophysiologic features of SYT2 mutations causing a treatable neuromuscular syndromeEvaluation of a novel calcium channel agonist for therapeutic potential in Lambert-Eaton myasthenic syndromeNon-paraneoplastic Lambert-Eaton myasthenic syndrome: a brief review of 10 cases.Clinical applications of immunoglobulin: update.Therapeutic Apheresis in Immunologic Renal and Neurological Diseases.Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer.New Cav2 calcium channel gating modifiers with agonist activity and therapeutic potential to treat neuromuscular disease.Lambert-Eaton myasthenic syndrome: mouse passive-transfer model illuminates disease pathology and facilitates testing therapeutic leads.Paraneoplastic syndromes of the neuromuscular junction: therapeutic options in myasthenia gravis, lambert-eaton myasthenic syndrome, and neuromyotonia.Pure Ocular Weakness as the Initial Manifestation of Lambert-Eaton Myasthenic Syndrome.
P2860
Q26752540-726F9D31-A4D3-46FB-BB20-8C050E57F521Q34206472-8AEF0697-F2AC-48AF-8813-A65033F565BFQ34437216-5AA0A903-EA4C-4566-AEB9-75D9D9E3C680Q35049590-8421C0C1-F0C2-4BE8-B981-095B499E9C47Q36331440-7D3C3423-EB25-4620-BB63-5DFC855E0EF9Q36938303-C3DAAF7E-6E87-49A4-8012-ADA0E6952C13Q37829651-2896FA15-FD35-4E89-8167-A45CDB431D18Q38050751-22F52753-F477-40AC-9AB4-46A9614E0C2DQ39025553-96157286-5603-4A79-AEFC-81420D6280C0Q39368677-8E9F91AD-05FB-4BB5-8C4F-76385660B9CDQ49791764-3232B10C-0CDD-43CF-99D9-6DEE3CA01AC6Q50073063-068AA3A0-0162-4EDE-BC12-40EB40EE1D63Q53118752-3B8CDBDE-F58B-4049-B181-6EFA70A5B81EQ55005032-E1EE188B-4ED6-447B-8721-553B264B02EB
P2860
Available treatment options for the management of Lambert-Eaton myasthenic syndrome.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
name
Available treatment options for the management of Lambert-Eaton myasthenic syndrome.
@ast
Available treatment options for the management of Lambert-Eaton myasthenic syndrome.
@en
Available treatment options for the management of Lambert-Eaton myasthenic syndrome.
@nl
type
label
Available treatment options for the management of Lambert-Eaton myasthenic syndrome.
@ast
Available treatment options for the management of Lambert-Eaton myasthenic syndrome.
@en
Available treatment options for the management of Lambert-Eaton myasthenic syndrome.
@nl
prefLabel
Available treatment options for the management of Lambert-Eaton myasthenic syndrome.
@ast
Available treatment options for the management of Lambert-Eaton myasthenic syndrome.
@en
Available treatment options for the management of Lambert-Eaton myasthenic syndrome.
@nl
P2093
P2860
P1476
Available treatment options for the management of Lambert-Eaton myasthenic syndrome
@en
P2093
Joop van Gerven
Luuk N A Willems
Paul W Wirtz
P2860
P304
P356
10.1517/14656566.7.10.1323
P407
P577
2006-07-01T00:00:00Z